Infliximab induction and maintenance therapy for ulcerative colitis: the ACT 2 trial
WJ Sandborn(Mayo Clinic in Arizona), J F Colombel(European CanCer Organisation), S. Hanauer(University of Illinois Chicago), GR Lichtenstein(University of Pennsylvania), Suzanne Travers, Walter Reinisch(Medical University of Vienna), D Rachmilewitz(Shaare Zedek Medical Center), A. Olson, Jewel Johanns(Johnson & Johnson (United States)), WJS de Villiers(University of Kentucky)
Cited by 51
Related Papers
Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2005|3.9k
Ustekinumab as Induction and Maintenance Therapy for Crohn’s Disease
|New England Journal of Medicine|2016|1.8k
Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2019|1.2k
Ustekinumab Induction and Maintenance Therapy in Refractory Crohn's Disease
|New England Journal of Medicine|2012|1.1k